Shares of Moderna (NASDAQ: MRNA) jumped 6.2% on Wednesday after the drugmaker announced that it had requested permission to administer its COVID-19 vaccine candidate to adolescents in Canada and the European Union.
Moderna said in May that a phase 2/3 clinical trial of its vaccine in adolescents demonstrated 93% efficacy against mild COVID-19 and 100% against a more severe classification of the disease among the study's nearly 2,500 participants who received its drug. The vaccine was also generally well tolerated, with no significant safety concerns identified during the trial.
Moderna is seeking the ability to distribute its coronavirus vaccine for adolescents. Image source: Getty Images.
Source Fool.com